top of page

Janssen - argenx Cusatuzumab Collaboration

Sexton Riley LLP Represents Janssen Affiliate Cilag GmbH International in Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

December 2018

​Sexton Riley LLP represented Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, in a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to develop and commercialize cusatuzumab (ARGX-110). Cusatuzumab is an investigational therapeutic antibody that targets CD70, an immune checkpoint implicated in numerous cancers, including hematological malignancies. Under the terms of the agreement, Janssen will jointly develop and globally commercialize cusatuzumab in AML, MDS, and potential future indications, as well as next generation CD70 antibodies. Janssen will make an upfront payment of $300 million USD and additional payments based upon the achievement of certain development, regulatory and sales milestones.

The Janssen press release is here.


bottom of page